contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dignitana-ab-publishes-q1-2024-interim-report

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Dignitana

Continued progress with increasing activity and awarenessFinancial highlights Q1 2024Net Sales amounted to 21.2 MSEK (21.5), a decrease of 2 percent over the same quarter in 2023.Operating Result...

Continued progress with increasing activity and awarenessFinancial highlights Q1 2024<ul><li>Net Sales amounted to 21.2 MSEK (21.5), a decrease of 2 percent over the same quarter in 2023.</li><li>Operating Result amounted to -5.0 MSEK (-3.5).</li><li>Net Result after financial items amounted to -5.1 MSEK (-3.9).</li><li>EBITDA for the First Quarter is negative at -1.1 MSEK (0.2).</li><li>Earnings per share were -0.07 SEK (-0.06).</li><li>Cash Balance amounted at 2.8 MSEK (11.7).</li><li>Average Daily Treatment Revenue (ADTR)* was 241 TSEK (242) in the quarter.</li></ul>Business highlights during the period<ul><li>Dignitana held an Extraordinary General Meeting to resolve on the rights issue and to obtain a bridge loan.</li><li>Dignitana convened Training Academy bringing distributors to Lund Headquarters.</li><li>DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana's Distribution partner.</li><li>Dignitana signed OncoMedical for distribution in Switzerland and Liechtenstein.</li><li>Preliminary result of DigniCap Delta study in Uruguay demonstrated very high efficacy compared to previous studies.</li><li>DigniCap Delta study is underway in Brindisi, Italy.</li><li>Dignitana nominated for Inaugural Texas Impact Enterprise Awards.</li><li>Dignitana invited to address MedTech innovation on a panel at SXSW® conference in Texas.</li></ul>Business highlights after the period<ul><li>Dignitana Rights Issue was fully subscribed at 19.1 MSEK before issue cost.</li><li>Fredrik Jonsson appointed as CEO beginning 1 May 2024 following resignation of Caterina Lowenadler.</li><li>Dignitana signed an exclusivity agreement with Konica Minolta as distributor for DigniCap in Japan.</li><li>Dignitana exhibited&nbsp;at the Oncology Nursing Congress in Washington, DC</li></ul>Key FiguresDIGNITANA GROUP Q1 2024 Q1 2023 Full year 2023 Net sales, TSEK 21,165 21,489 86,063 Total revenues, TSEK 21,288 21,605 89,025 Net profit after -5,056 -3,938 -17,228 financial items, TSEK Cash and bank balances, 2,839 11,726 6,027 TSEK Earnings per share -0.07 -0.06 -0.25 before and after dilution, SEK Average Daily Treatment 241 242 239 revenue*, TSEK*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.All financial reports are available at&nbsp;www.dignitana.com/investor-relations/financial-reports/This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2024 08:00 CET.